• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    SC 13G/A 1 tv02272-westpharmaceuticalse.htm SCHEDULE 13G/A westpharmaceuticalservicesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 14)*

    Name of issuer:  West Pharmaceutical Services Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  955306105

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  955306105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    97,902

    7.  SOLE DISPOSITIVE POWER

    8,685,103

    8.  SHARED DISPOSITIVE POWER

    317,529

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,002,632

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    12.17%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    West Pharmaceutical Services Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    530 Herman O. West Drive
    Exton, PA 19341-0645

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    955306105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $WST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    4/11/2023$330.00 → $400.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Financials

    Live finance-specific insights

    See more
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West Announces Executive Leadership Appointments

      EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

      5/12/22 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Citigroup initiated coverage on West Pharm with a new price target

      Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00

      1/8/25 8:35:06 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Pucci Paolo was granted 1,071 shares, increasing direct ownership by 11% to 10,947 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:00:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Haugen Janet Brutschea was granted 1,071 shares, increasing direct ownership by 433% to 1,318 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:54:17 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/13/24 5:17:38 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/14/23 12:37:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/22 8:47:14 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    SEC Filings

    See more
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by West Pharmaceutical Services Inc.

      10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 4:19:45 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 7:56:20 AM ET
      $WST
      Medical/Dental Instruments
      Health Care